Esperion Therapeutics. has filed a patent for a method of preparing and making a pharmaceutical material containing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. The patent also includes compositions and methods of treating diseases using this material. The claim specifically focuses on the use of this material to lower low-density lipoprotein cholesterol (LDL-C) in humans. GlobalData’s report on Esperion Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Esperion Therapeutics, NSAID cancer drugs was a key innovation area identified from patents. Esperion Therapeutics's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Method of lowering ldl-c using crystalline compound (formula v)
A recently filed patent (Publication Number: US20230250043A1) describes a method for lowering low-density lipoprotein cholesterol (LDL-C) in humans. The method involves administering a pharmaceutical material that contains a crystalline form of a compound known as formula (V). This compound has been found to effectively reduce LDL-C levels in the body.
The crystalline form of the compound is characterized by an X-ray powder diffraction pattern that closely matches the one shown in FIG. 4 of the patent. It also has a melting point onset in the range of 90°C to 94°C, as determined by differential scanning calorimetry.
The pharmaceutical material contains the compound of formula (V), or a pharmaceutically acceptable salt of it, in a high concentration. In particular, the compound or salt makes up more than 99.5% by weight of the total weight of the pharmaceutical material. In some embodiments, the concentration is even higher, with amounts greater than 99.7% or 99.9% by weight.
The pharmaceutical material is also highly pure, with less than or equal to 0.2% by weight of unknown impurities. This ensures that the material is of high quality and free from contaminants.
In addition to the compound of formula (V), the method may involve the administration of a second therapeutic agent, specifically ezetimibe. This combination therapy may further enhance the reduction of LDL-C levels in patients.
Overall, this patent presents a method for effectively lowering LDL-C levels in humans using a pharmaceutical material containing a specific crystalline form of a compound. The high concentration and purity of the compound in the material, along with the potential addition of ezetimibe, make this method a promising approach for managing LDL-C levels and potentially reducing the risk of cardiovascular diseases associated with high cholesterol.
To know more about GlobalData’s detailed insights on Esperion Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
